

1 **Gut resident *Escherichia coli* profile predicts the eighteen-**
2 **month probability and antimicrobial susceptibility of urinary**
3 **tract infections.**

4 Veronika Tchesnokova¹, Lydia Larson¹, Irina Basova¹, Yulia Sledneva¹, Debarati
5 Choudhury¹, Thalia Solyanik¹, Jennifer Heng¹, Teresa Cristina Bonilla¹, Isaac
6 Pasumansky¹, Victoria Bowers¹, Sophia Pham¹, Lawrence T. Madziwa^{2,3}, Erika
7 Holden^{2,3}, Sara Y. Tartof^{4,5}, James D. Ralston^{2,3} and Evgeni V. Sokurenko^{1*}

8 ¹Department of Microbiology, University of Washington School of Medicine, 1705
9 NE Pacific St., Seattle, WA 98195, USA

10 ²Kaiser Permanente Washington, 2715 Naches Ave. SW, Renton, WA 98057, USA

11 ³Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Suite
12 1600, Seattle, WA 98101-1466, USA

13 ⁴Kaiser Permanente Southern California, Department of Research & Evaluation,
14 Pasadena, 100 S Los Robles, Pasadena, CA 91101, USA

15 ⁵Kaiser Permanente Bernard J. Tyson School of Medicine, Department of Health
16 Systems Science, 100 S Los Robles, Pasadena, CA 91101, USA

17

18 * **Corresponding author:** Evgeni V. Sokurenko, evs@u.washington.edu

19 **Short title:** Gut E. coli Profile Predicts 18-Month UTI Probability &

20 Antimicrobial Susceptibility

21 **Abstract**

22 **Background:** Community-acquired UTI is the most common bacterial infection
23 managed in general medical practice that can lead to life-threatening outcomes.
24 While UTIs are primarily caused by *Escherichia coli* colonizing the patient's gut,
25 it is unclear whether the gut resident *E. coli* profiles can predict the person's
26 risks for UTI and optimal antimicrobial treatments. Thus, we conducted an
27 eighteen-month long community-based observational study of fecal *E. coli*
28 colonization and UTI in women aged 50 years and above.

29 **Methods and Findings.** We enrolled a total of 1,804 women distributed among
30 age groups 50-59 yo (437 participants), 60-69 yo (632), 70-79 yo (532), and
31 above 80 yo (203), lacking antibiotic prescriptions for at least one year. The
32 provided fecal samples were plated for the presence of *E. coli* and other
33 enterobacteria resistant to trimethoprim/sulfamethoxazole (TMP/STX),
34 ciprofloxacin (CIP) and 3rd generation cephalosporins (3GC). *E. coli* was also
35 characterized as belonging to the pandemic multi-drug resistant clonal groups
36 ST131 (subclone H30) and ST1193. Following sample collection, the women
37 were monitored for 18 months for occurrence of UTI.

38 *E. coli* was cultured from 90.8% fecal samples, with 24.1% containing bacteria
39 resistant to TMP/STX, 19.4% to CIP, and 7.9% to 3GC. In 62.5% samples, only
40 all-susceptible *E. coli* were present. Overall, there were no age-related
41 differences in resistance prevalence. However, while the total *E. coli* H30 and

42 ST1193 carriage rates were similar (4.3% and 4.2%, respectively), there was a
43 notable increase of H30 carriage with age ($P = .001$), while carriage decreased
44 with age for ST1193 ($P = .057$).

45 Within 18 months, 184 women (10.2%) experienced at least one episode of UTI
46 - 10.9% among the gut *E. coli* carriers and 3.0% among the non-carriers
47 ($P=.0013$). The UTI risk among carriers of *E. coli* H30 but not ST1193 was
48 significantly above average (24.3%, $P = .0004$). The UTI probability increased
49 with age, occurring in 6.4% of 50-59 yo and 19.7% of 80+ yo ($P<.001$), with the
50 latter group being especially at high risk for UTI, if they were colonized by *E.*
51 *coli* H30 (40.0%, $P<.001$).

52 *E. coli* was identified in 88.1% of urine samples, with 16.1% resistant to
53 TMP/STX, 16.1% to CIP, 4.2% to 3GC and 73.1% to none of the antibiotics.
54 Among tested urinary *E. coli* resistant to antibiotics, 86.1% matched the
55 resistance profile of *E. coli* in the fecal samples, with the clonotyping and whole
56 genome sequencing confirming the matching strains' identity. Positive predictive
57 value (PPV) of using gut resistance profiles to predict UTI pathogens'
58 susceptibility to TMP/STX, CIP, 3GC and all three antibiotics were 98.4%,
59 98.3%, 96.6% and 95.3%, respectively. Corresponding negative predictive
60 values (NPV) were 63.0%, 54.8%, 44.4% and 75.8%, respectively. The AUC
61 ROC curve values for the accuracy of fecal diagnostic testing for the prediction
62 of UTI resistance ranged .86-.89. The fecal test-guided drug-bug mismatch rate

63 for empirical (pre-culture) prescription of TMP-SXT or CIP is reduced to $\leq 2\%$ in
64 89.6% of patients and 94.8% of patients with an optional 3GC prescription.

65 **Conclusion.** The resistance profile and clonal identity of gut colonizing *E. coli*,
66 along with the carrier's age, can inform personalized prediction of a patients'
67 UTI risk and the UTI pathogen's antibiotic susceptibility within an 18-month
68 period.

69 Introduction

70 The personalized or precision medicine approach is based on defining the
71 potential risks, expected outcomes, and optimal treatment of diseases based on
72 an individual's unique biomarkers, which are usually genetically determined but
73 can also depend on and behavioral factors [1]. The indigenous microbiota that
74 colonizes the gut, vagina or other body compartments is considered an integral
75 component of the human organism, influencing various aspects of individuals'
76 health (for review see [2, 3]). At the same time, the resident microflora serves
77 as a major source of opportunistic bacterial pathogens for the host, including
78 those resistant to multiple antibiotics [4-6]. However, it remains unclear how the
79 identification of certain bacterial species and/or sub-species lineages in the
80 colonizing microbiota can predict the person's risks for developing specific
81 clinical infections or guide antibiotic treatment choices, especially in the era of
82 continuously increasing antimicrobial resistance.

83 Gut resident microbiota, *Escherichia coli* and other enterobacterial species in
84 particular, is the main reservoir for strains causing the most common bacterial
85 infection treated by general practitioners - community-acquired urinary tract
86 infections (UTIs) with the estimated total annual incidence rate of up to 7% the
87 USA and globally [7-10]. Postmenopausal women, typically aged 50 or older,
88 face a particularly high risk of developing severe and drug-resistant forms of
89 UTIs [11, 12]. While acute uncomplicated cystitis is the most common form of
90 UTI, its very high incidence places a substantial financial burden on the

91 healthcare system, especially if the initial treatment choice was not effective
92 [10, 13]. Also, more severe UTI forms such as recurrent cystitis, pyelonephritis,
93 or urosepsis (an estimated one-third of sepsis cases begin as UTIs) significantly
94 contribute to the overall costs associated with UTIs, particularly in elderly [10,
95 13, 14].

96 UTIs are almost exclusively treated with antibiotics, thus representing a primary
97 single reason for antibiotic use in humans [15]. However, antimicrobial
98 resistance has reached pandemic proportions in the last few decades,
99 contributing to increased mortality rates and healthcare costs (estimated at
100 approximately \$2,000 per ineffective prescription) [16-19]. Because determining
101 the resistance profiles of infecting bacteria takes 2-3 days, physicians must
102 resort to the empirical (pre-culture) choice of antibiotics. Typically, empirical
103 treatment is inherently imprecise as it is not informed by the specific resistance
104 profile of infecting bacteria but relies on general resistance patterns in the local
105 community [20]. For empiric treatment of uncomplicated UTI, the Infectious
106 Diseases Society of America (IDSA) recommends treatment with an antibiotic if
107 the local resistance prevalence in *E. coli* is no more than 20%, whereas for
108 pyelonephritis or other severe forms, the recommended resistance prevalence
109 should be $\leq 10\%$ [20-22]. Unfortunately, the resistance to commonly used
110 antibiotics is now often well above 20% and the empiric guesswork results in the
111 prescription of ineffective antibiotics ('drug-bug mismatches') in 15-35% of
112 cases, leading to increased health care cost and overuse of last-line, broad-
113 spectrum antimicrobials [16, 18, 19].

114 It has been well-established that extraintestinal pathogenic *E. coli* and other
115 enterobacteria causing UTIs derive from the gut, where they reside as part of
116 the commensal microbiota, typically existing as a consortium of multiple strains
117 (for review see [23]). These commensals include *E. coli* strains resistant to
118 antibiotics, and their presence in the gut may not be contingent upon antibiotic
119 use by the individual [24-28]. Among the antibiotic resistant *E. coli* causing
120 UTIs, strains of two multi-drug resistant clonal groups (genetic families)
121 dominate in the USA and globally – one is the sequence types ST131-H30R/Rx
122 (aka ST131 clade C1/C2; *E. coli* H30 for further) and ST1193 [24, 25, 27, 29-
123 33]. Their rampant spread was noted in the first and second decades of this
124 century, respectively, with fluoroquinolone resistance being the signature of
125 both clonal groups. It has been hypothesized that the high prevalence and
126 global spread of *E. coli* H30 and ST1193 could be connected to their success as
127 gut colonizers [25, 34-36].

128 Multiple studies have estimated the risks of extraintestinal infections associated
129 with gut carriage of multi-drug resistant *E. coli*. Generally, these studies have
130 focused on the risks of bacteremia and included samples from hospital/ICU-
131 admitted patients and/or those who underwent various organ transplant
132 procedures [37-40]. The correlation between gut carriage and consequent drug-
133 resistant infections has been sufficiently strong to motivate studies on gut
134 decolonization of patients at risk, employing methods such as fecal microbiome
135 transplantation, probiotics, and/or phage therapies [37, 41-44]. To our
136 knowledge, however, there have been no observational prospective studies to

137 assess the value of characterizing gut-colonizing bacteria for predicting the
138 risks and guiding the antimicrobial treatment of such a vastly common antibiotic-
139 treated medical condition as UTI. Additionally, while it is well-known that certain
140 risk groups for UTI exist, such as patients with diabetes, postmenopausal
141 women or, the elderly [45-47], it is unclear to what extent the probability of UTI
142 in those groups are also defined by the species or clonal type of gut-colonizing
143 enterobacteria.

144 Here, we present the outcomes of an 18-month prospective observational study
145 on the risk for UTI women above 50 yo and the correlation between the clonal
146 and resistance profiles of *E. coli* in pre-collected fecal samples and those
147 isolated from the follow-up clinical urine samples. The study group included
148 1,804 women receiving out-patient care in the Kaiser Permanente system in
149 Washington State, USA (KPWA), serving mostly the metropolitan Seattle/Puget
150 Sound Area, who had not received any antibiotics for at least one year before
151 providing the fecal sample. We demonstrate that the UTI risk, while dependent
152 on age, varied considerably based on the clonal identity of gut-colonizing *E.*
153 *coli*. Additionally, determining the resistance profile of gut *E. coli* significantly
154 improves the accuracy of resistance prediction for UTI-causing strains against
155 three commonly used antibiotics: trimethoprim/sulfamethoxazole (TMP/STX),
156 ciprofloxacin (CIP), and 3rd generation cephalosporins (3GC). Thus, we believe
157 that the analysis of gut microbiota for the presence, resistance profile, and
158 clonal identity of resident *E. coli* shows potential for a personalized medicine
159 approach in the clinical management of UTI, empowering antimicrobial

160 stewardship efforts and, potentially, developing effective means for infection
161 prevention.

162 **Methods**

163 ***Study design and participants.*** This prospective cohort study from May 1,
164 2021 through December 31, 2021 was conducted among women aged 50 years
165 and older enrolled in Kaiser Permanente Washington (KPWA). One-year
166 membership prior to enrollment was required to clinical and demographic data
167 prior to baseline. Besides enrollment, age and gender, exclusion criteria
168 included any antibiotic prescription, UTI and placement in a long-term care
169 facility within a year prior to enrollment in the study. This study was approved
170 by the KPWA) Research Institute Institutional Review Board. The procedural
171 details pertaining to the mailing of study kits to participants are described in the
172 previous manuscript [24].

173 ***Processing of fecal samples and typing of fecal E. coli*** was described in
174 detail previously [24]. Briefly, fecal samples were plated on either pre-poured
175 HardyCHROM™ UTI agar plates (Hardy Diagnostic, USA) or plates prepared
176 from HiChrome™ UTI Agar (HiMedia Laboratories Pvt, Ltd.) supplemented with
177 ciprofloxacin (CIP, 0.5 mg/L), trimethoprim/sulfamethoxazole (TS, 4/76 mg/L),
178 ceftazidime (CAZ, 8 mg/L), ceftriaxone (CTX, 2 mg/L). Plates were incubated
179 16-20h at 37°C, and single colonies (SCs) morphologically identified as
180 potential *E. coli* were cultured, saved and tested further for (a) resistance to

181 CIP, TMP/STX and 3rd generation cephalosporins (3GC – CAZ and CTX), (b)
182 clonality based on sequencing of four loci – *fumC*, *fimH*, *gyrA* and *parC*, as
183 described previously [24].

184 ***Processing of clinical urine samples and typing of urine E. coli.*** If a study
185 participant submitted a urine sample to KPWA clinical laboratory, a routine
186 urinalysis test was performed, followed by culture and sensitivity testing if
187 required. Starting February 2022, the UW laboratory was provided an aliquot of
188 the urine sample, which was processed using the same protocol as fecal sample
189 described above, adding *E. coli* clonality where applicable to sample
190 information.

191 ***UTI identification.*** The incidence of urinary tract infections in study
192 participants was deduced from their electronic health records (EHRs).
193 Records were examined once all participants had surpassed 18 months
194 following the submission of the fecal sample. UTI was characterized based
195 on the criteria outlined in Bruxvoort et al [7], including UTI diagnosis codes,
196 antibiotic prescriptions, urinalysis test results, and culture findings.

197 ***Resistant E. coli isolates comparison using whole genome sequencing.***
198 Whole genome sequencing was conducted using the Illumina MiSeq platform
199 following the manufacturer's guidelines. Genomic DNA libraries were
200 prepared using the Nextera XT Library Prep Kit (Illumina, CA). Raw data
201 were uploaded to the Enterobase database
202 (<https://enterobase.warwick.ac.uk/>) for genome assembly and allele calling

203 processes. Core gene sequences were utilized to assess the phylogenetic
204 relationship among isolates within the same clones.

205 **Search for sensitive *E. coli* clones within fecal samples.** Fecal samples
206 were examined to identify the presence of the *E. coli* clone responsible for
207 UTI in the participant. Three methods were employed. Firstly, a minimum of
208 two individual single colonies were isolated directly from the sample during
209 initial processing. These colonies were then screened for resistance profiles
210 and clonal identity. If these isolated colonies did not match the
211 uropathogenic *E. coli* clone, further isolation and screening of 9-28
212 (averaging 13) individual colonies were conducted. Secondly, the
213 uropathogenic *E. coli* strains were subjected to testing for resistance against
214 a broader spectrum of antibiotics, including ampicillin (50 and 100 mg/L),
215 rifampin (2 and 4 mg/L), tetracycline (16 mg/L), cefazoline (4 and 8 mg/L),
216 chloramphenicol (16 and 32 mg/L), kanamycin (12.5 and 25 mg/L),
217 gentamicin (15 mg/L), spectinomycin (15 mg/L), streptomycin (50 mg/L),
218 trimethoprim (8 and 16 mg/L), and sulfamethoxazole (80 and 160 mg/L).
219 Subsequently, fecal samples were plated on the antibiotic of interest to
220 search for isolates exhibiting the same resistance profile. Thirdly, fecal
221 samples were resuspended in phosphate-buffered saline (PBS) and between
222 10^3 - 10^4 cfu/plate were cultured on McConkey agar. Plates were divided into
223 sectors, and bacteria from each sector were collected and re-suspended in 1
224 mL PBS. A 100 μ L aliquot of this suspension was used for DNA purification
225 using 5% Chelex 100 (Bio-Rad, Richmond, CA) [48]. The purified DNA was

226 then subjected to qPCR to detect the presence of urinary clone-specific loci
227 and/or SNPs. In the event of a positive reaction, the saved bacterial
228 suspension was plated again to obtain and test individual single colonies.

229 **Whole genome sequencing.** Matching sets of *E. coli* isolates from clinical
230 urine samples and predating fecal samples underwent sequencing on
231 Illumina MiSeq platform using MiSeq 600 cycle v3 kit (Illumina). Raw reads
232 were uploaded to Enterobase database (<https://enterobase.warwick.ac.uk/>)
233 where they were assembled. The core genes were then downloaded from
234 Enterobase and analyzed for sequence identity. The trees were built using
235 MEGA v7 software. Enterobase uberstrain names are listed in Table S3.

236 **Statistical analysis.** Chi-square test was used to evaluate 2x2 comparisons.
237 Logistic regression was used to analyze the prevalence of different *E. coli*
238 strains and the incidence of UTI among participants across different age
239 groups. The analysis was conducted using STATA 14.2 Software (StataCorp,
240 Texas, USA).

241 **Results**

242 **Antibiotic resistant *E. coli* are carried at high rates by women without**
243 **recent exposure to antibiotics.** We collected fecal samples from 1,804 women
244 of age 50 years or above who did not take antibiotics for at least one year prior
245 to enrollment. Among the enrollees, 437 women (24%) were of age 50-59, 632

246 (35%) aged 60-69, 532 (30%) aged 70-79 and 203 (11%) aged 80 and above
247 (Table 1) (Fig S1A).

248 As expected, *E. coli* was present in a vast majority of the fecal samples (90.8%
249 on average) across all age groups, with a slight but statistically significant
250 decreased *E. coli* carriage observed for younger enrollees (Table 1) (Fig S1B).
251 The *E. coli* positive samples were tested for the presence of any resistance to
252 TMP/STX, CIP and 3GC. In 62.5% samples, all *E. coli* were sensitive to all three
253 antibiotics, 24.1% samples contained *E. coli* resistant to TMP/STX: 19.4% to
254 CIP and 7.9% to 3GC (Table 1), with 10.8% having *E. coli* resistant to more than
255 one antibiotic. There were no differences between the age groups in prevalence
256 of samples with resistant *E. coli* (Table 1) (Fig S1C-E).

257 Among the *E. coli*-positive fecal samples, clonal groups *E. coli* H30 and ST1193
258 were found among 4.3% and 4.2%, respectively, with a combined prevalence of
259 43.4% among the samples with CIP-resistant *E. coli*. The gut carriage of *E. coli*
260 H30 significantly increased with age ($P = .001$), ranging from 2.3% in the 50-59
261 yo group to 7.9% in women of 80+ yo (Table 1) (Fig S1F), while an opposite
262 age-dependence tendency was observed for the carriage of ST1193, with 5.2%
263 in the youngest group but only 2.1% ($P = .057$) in the elder group (Table 1) (Fig
264 S1G).

265 Thus, a third (34.1%) of women 50 yo and older without recent exposure to
266 antibiotics carry gut *E. coli* that is resistant to at least one of the three
267 commonly used antibiotics, with no overall differences in the resistant *E. coli*

268 carriage between different age groups. At the same time, the older women
269 tended to carry significantly more frequently *E. coli* from the multi-drug resistant
270 clonal group ST131-H30.

271 ***The 18-month probability of UTI occurrence depends on E. coli presence***
272 **and clonality.** During the follow up 18 months of observation, 5-17 enrollees
273 per month were diagnosed with UTI (Fig S2), with a total 184 women (10.2%)
274 having at least one episode of UTI (Table 2). All urines were collected from
275 women as outpatients; thus, all UTI cases qualify as being community acquired.
276 The frequency of UTI cases significantly increased with age (Fig S1H),
277 occurring in 1 in 5 (19.7%) women of age 80+ (Table 2). Interestingly, across
278 the age groups UTI occurred nearly four-fold more frequently among women
279 who carried *E. coli* in the gut than in those with no *E. coli* presence in feces.

280 In the total cohort of enrollees, the 18-month rate of UTI did not significantly
281 differ between the carriers of all-sensitive *E. coli* and those carrying *E. coli*
282 resistant to any of the tested antibiotics (Table 2). In contrast, the rate of UTI
283 was nearly significantly higher than average for the carriers of multi-drug
284 resistant *E. coli* H30 (24.3%; $p=.0004$). Notably, the rate of UTI among the
285 carriers of ST1193 was at the average level.

286 When analyzed by age groups, the rates of UTI increased with age among the
287 carriers of all-sensitive, TMP/STX-resistant, and CIP-resistant *E. coli* but the
288 increase with age did not reach the statistical difference across the 3GC
289 carriers (Fig S1I-M). While the UTI rates did not change with age among the

290 carriers of ST1193, the UTI rates increased with age among the *E. coli* H30
291 carriers, reaching the 18-month occurrence of 36.4% in women or age 70-79
292 and 40.0% of age 80+. Moreover, in the two elder groups of enrollees, the UTI
293 probability for the *E. coli* H30 carriers was significantly higher than for carriers
294 of any other *E. coli*.

295 Thus, nearly 1 in 8 of women aged 50 and above, who are not taking antibiotics
296 but carry *E. coli* in their gut, would experience a UTI within an 18-month period.
297 In the older women, however, the overall UTI frequency increases up to two-fold
298 overall and nearly four-fold in those who are colonized with the multi-drug
299 resistant *E. coli* H30.

300 ***E. coli* is the predominant and most resistant urinary pathogen.** To
301 evaluate the identity and resistance profiles of urinary pathogens we analyzed a
302 total of 134 bacteriology-positive urine samples submitted by our study
303 enrollees to the clinical laboratory as part of the initial UTI diagnostics. The
304 bacteriology-positive samples were evenly spread across the 18 months of
305 observation (Fig S2). *E. coli* was identified in 118 (88.1%) of the samples and
306 was predominant at a similarly high level across all ages. Out of the remaining
307 16 samples, more than half (9 samples) contained *Klebsiella* spp., with the rest
308 having *Citrobacter* spp. (in 2 samples), *P. mirabilis* (3), *Salmonella enterica* (1)
309 and *E. faecalis* (1). Among the urine-isolated *E. coli*, 82 (69.5%) isolates were
310 sensitive to all three antibiotics, 19 (16.1%) were resistant to TMP/STX, 19
311 (16.1%) to CIP and 5 (4.2%) to 3GC (Table 3), with 6 (4.6%) resistant to

312 multiple antibiotics (Table S1). Among the non- *E. coli* urinary pathogens, none
313 were resistant to any of the tested antibiotics, which is significantly lower
314 ($p=.008$) than the proportion of resistant *E. coli* among the clinical isolates
315 (Table S2).

316 Thus, in the community-acquired UTI among the women aged 50 and above, *E.*
317 *coli* is both the predominant pathogen and responsible for most of the antibiotic-
318 resistant infections.

319 ***Resistance profile of E. coli in the urine samples match those in fecal***
320 ***samples due to the strains' identity.*** Baseline fecal *E. coli* was available from
321 all 118 enrollees with *E. coli* positive UTIs. Among the fecal samples, 64.2%
322 contained all-sensitive gut *E. coli*, 20.3% contained *E. coli* resistant to
323 TMP/STX, 23.3% to CIP and 6.8% to 3GC. There was a highly significant ($P <$
324 $.001$) overlap between the presence of resistant *E. coli* in urine and the
325 corresponding fecal samples – out of 36 urine isolates resistant to any of the
326 three antibiotics, 31 (86.1%) had an *E. coli* with the same resistance pattern in
327 the corresponding fecal samples. Among them, 89.5% of urine isolates had an
328 *E. coli* with a matching resistance to either TMP/STX or FQ and 80% for the
329 resistance to 3GC (Table 3). Similarly, in 83.7% cases when the urine *E. coli*
330 was sensitive to all three antibiotics, there was no resistant *E. coli* in the
331 corresponding fecal sample.

332 The high-level correspondence between the resistance phenotypes of fecal and
333 urinary samples obtained within 18 months of each other suggests that the

334 same *E. coli* strain is present in both sample types. Indeed, in 21 cases when
335 both fecal and urine sample were available for genetic clonotyping and
336 contained isolates resistant to the same antibiotic(s), all of them were of the
337 same clonal sub-group (Table S1). We compared 9 pairs of such clonally
338 matching strains by whole genome sequencing and confirmed that the same-
339 person urine and fecal samples are much closer genetically to one another than
340 other strain pairs even of the same clonotype (Fig S3).

341 Five sample pairs with mismatched resistance profiles between fecal and UTI
342 isolates were evenly spread across the 18 months of observation, obtained at
343 months 4, 6, 13, 16 and 17 (Table S1). Out of those, 3 samples were available
344 for the clonal identity, with all determined to be of a different nature.

345 Thus, there is a high correspondence between the resistance profiles of gut
346 resident *E. coli* and UTI isolates obtained from the same person within 18
347 months from fecal sample.

348 ***Urinary E. coli prediction based on fecal E. coli antibiotic resistance***
349 ***(FECAR) testing.*** Because only a small portion of *E. coli* from urine samples did
350 not have a fecal *E. coli* with a matching resistance profile, positive predictive
351 values (PPV) for the susceptibility to antibiotics ranged between 94.5% for the
352 all-sensitive urine isolates to 99.1% for those sensitive to 3GC (Table 4). The
353 negative predictive values (NPV; prediction of non-susceptibility) ranged
354 between 71.1% for any of the three antibiotics and 44.4% for 3GC. Notably,
355 PPV and NPV remained at similar levels for the resistance prediction for the

356 entire set of 134 urinary pathogens (i.e. including the 16 urine samples with
357 non- *E. coli* bacteria, all of which as indicated above, were sensitive to the three
358 antibiotics), because vast majority of the corresponding fecal samples had only
359 all-sensitive *E. coli* (Table 4; Table S2). We estimated the diagnostic value of a
360 potential fecal *E. coli* antibiotic resistance (FECAR) test to determine the
361 resistance of UTI-causing pathogens in our cohort. The values of AUC (Area
362 Under the Receiver Operating Characteristic (ROC) Curve) for the FECAR test
363 ranged from .86-.89, i.e., at the 'excellent' level [49].

364 We analyzed how, hypothetically, the FECAR testing could improve the
365 accuracy of empirical (pre-culture) treatment of the UTI cases in our study
366 population by guiding the antibiotics choice. Using FECAR testing, TMP/STX,
367 CIP and 3GC would be '*recommended*' for use in nearly 78%, 76% and 93% of
368 all UTI cases, respectively, based on the absence of resistant *E. coli* in the
369 corresponding fecal samples (Table 5). The FECAR-guided antimicrobial choice
370 would lead to a drug-bug mismatch in only 1.9%, 2.0% and 0.8% of cases,
371 respectively. Either TMP/STX or CIP would be recommended in almost 90%
372 case and at least one of the antibiotics in 95% cases (Table 5).

373 Based on the 2022 annual antibiogram of *E. coli* isolated in the clinical
374 microbiology laboratory of all KPWA enrollees, the local resistance to all three
375 antibiotics is $\leq 20\%$ - 16.9% to TMP/STX, 12.8% to CIP, and 5.8% to 3GCR.
376 Thus, any of them can be recommended for the UTI treatment in our enrollees,
377 assuming all patients had an uncomplicated cystitis. In our cohort, however,

378 such FECAR-unguided treatment would lead to a drug-bug mismatch in 14.2%
379 for TMP/STX and CIP, which is significantly higher than the mismatch resulted
380 from the FECAR guidance ($P = .0009$ and $P = .0011$, respectively). For the
381 unguided 3GC treatment the mismatch would occur in 3.7% of cases, which is
382 not significantly higher ($P = .0963$).

383 In contrast, the use of TMP/STX, CIP and 3GC would be '*not recommended*' by
384 FECAR in 21.6%, 23.9% and 6.8%, respectively, due to the presence of
385 resistant *E. coli* in feces. While in 41.4, 46.9 and 55.6%, respectively, of the
386 corresponding UTI cases, the isolate happened to be susceptible to the
387 antibiotic, the antibiotics use in the not recommended cases would result in
388 drug-bug mismatch rate that is significantly above the mismatch rates resulted
389 from the unguided treatment, well exceeding the 20% rates considered to be
390 acceptable by the IDSA recommendations.

391 **Discussion**

392 Our study demonstrates that the presence and clonal identity of gut *E. coli*
393 contribute to the risk of UTI. Moreover, although the human gut is often
394 colonized by multiple strains of *E. coli* simultaneously (as discussed in detail
395 below), the presence/absence of gut *E. coli* resistant to commonly used
396 antibiotics could be used for predictive diagnostics of urinary pathogen
397 susceptibility, within 18 months of the fecal testing and with an 'excellent level'
398 of test accuracy. Thus, such testing can support a personalized medicine

399 approach to UTI management by improving prediction of UTI infection and
400 tailoring the empiric treatment choice.

401 Although the time of reaching menopause varies widely, women aged 50 and
402 above are generally considered to be in the range of premenopausal to post-
403 menopausal. Due to estrogen decline, a rise in vaginal pH, higher urine
404 retention in the bladder, and other factors, postmenopausal women are known
405 to be at an increased risk for severe, complicated, and drug-resistant forms of
406 UTI [50, 51]. All women selected for the study did not have exposure to
407 antibiotics and were not diagnosed with UTI or hospitalized for any reason at
408 least one year prior to the study enrollment. Although these criteria may result
409 in a study population with lower risk compared to a general population women
410 50 years and older, this would rather result in an underestimate of the potential
411 impact of FECAR, which could be expected to have an even higher impact in a
412 population with more frequent infection and therefore higher probability of
413 resistance.

414 As expected, *E. coli* was isolated from the fecal sample of most women. Though
415 a clear minority, *E. coli* non-carriers were ~2-times more common among
416 women younger than 70. This is a novel finding, the underlying reason for which
417 remains unclear. Also novel is the follow-up observation that *E. coli* non-carriers
418 are about three times less likely to have UTIs than carriers, strongly suggesting
419 that *E. coli* is the major causative species for UTI. These data provide further

420 support that the probability of UTI depends on and, thus, may be predicted by
421 the presence or absence of gut-colonizing *E. coli*.

422 We concentrated here on three antibiotics commonly used for the CA-UTI
423 treatment. TMP/SMX (Bactrim) is suggested as the first line antibiotic for
424 uncomplicated UTI, similar to nitrofurantoin or fosfomycin [52]. CIP is suggested
425 as an alternative drug of choice when the first line antibiotics cannot be used for
426 any reason, or as the first-choice antibiotic if pyelonephritis is suspected,
427 usually combined with a single-dose boost of parenteral 3GC. However, as
428 mentioned in the Introduction, the empirical use of antibiotics is recommended
429 for the treatment of cystitis only if the local resistance prevalence is below 20%,
430 or below 10% for the treatment of pyelonephritis [21].

431 Surprisingly, even though study participants did not take antibiotics for at least
432 a year prior enrollment, just over a third of them carried gut *E. coli* resistant to
433 one or more of the three antibiotics. Interestingly, the carriage of resistant *E.*
434 *coli* did not differ significantly between age groups, in accordance with a lack of
435 evidence that increased age is a risk factor for carriage of drug-resistant
436 bacteria [28]. However, the lack of association could be because our study enrolled
437 only women who had not taken antibiotics in the year prior.

438 The most striking difference between the age groups was found in the carriage
439 of *E. coli* belonging to the pandemic multi-drug resistant clonal groups *E. coli*
440 H30 and ST1193. *E. coli* H30 is estimated to have emerged in the 1990s gained
441 notoriety as the main cause of antibiotic resistant UTIs globally since early

442 2000s [33, 53]. Independently of resistance, it is also associated with
443 complicated and severe forms of UTIs, such as recurrent cystitis, pyelonephritis,
444 urosepsis, and infections in diabetic and immunocompromised patients [54].
445 ST1193 emerged later than *E. coli* H30 but started to challenge the latter in
446 global UTI predominance in the mid-late 2010s [29, 31]. It has been proposed
447 that the phenomenal global spread of both *E. coli* H30 and ST1193 is
448 associated with their success as gut colonizers, possibly connected to the
449 mutations responsible for CIP resistance [35, 36]. The fact that *E. coli* H30 is
450 significantly more commonly carried by older women corresponds to our
451 previous findings in a smaller prior study [11].

452 The underlying reason for the age differences in *E. coli* H30 and ST1193
453 carriage is not yet known. However, we believe that this observation suggests
454 that resistance *per se* might not be the main selective factor for gut colonization
455 and other host factors, e.g., immune status, may be in play. Whatever the
456 underlying reason for the different carriage rates it's important for predicting the
457 occurrence of UTI. The overall 18-month incidence of UTIs in *E. coli* H30
458 carriers was twice as high as the average – 1 in 5 women. This was due to an
459 astoundingly high rate of *E. coli* H30 UTIs in women aged 70+, occurring in
460 more than a third of the enrollees, higher than in almost every other category of
461 *E. coli* carriers of this age. Interestingly, the UTI rates for ST1193 carriers were
462 not different from the average, potentially reflecting differences either in the
463 urovirulence potential of the strains or in the host defense status of the
464 colonized populations.

465 The significantly higher rate of UTIs for *E. coli* H30 illustrates the importance of
466 predicting UTI based on the clonal identity of the resident strain, in combination
467 with considering host demographics. While we did not examine the UTI
468 incidence for other major clonal groups of *E. coli*, this finding highlights the
469 value of examining the microbiota composition beyond large taxonomic groups
470 or even species (as mostly done by microbiome studies) but at the sub-species,
471 clonal group level that we propose to term as a ‘clonobiome’ analysis [55]. As
472 with most human pathogens, the *E. coli* species is clonal by nature, with the
473 majority of strains belonging to a relatively limited number of genetically well-
474 defined and closely related clonal groups (i.e., Sequence Types or STs) that
475 can significantly differ from each other in virulence potential and/or antimicrobial
476 resistance profiles [56, 57]. Thus, by defining the clonal diversity of the
477 colonizing strains, the clonobiome approach allows us to assess more
478 accurately the clinical risks and treatment options associated with the resident
479 microbiota. To note, it was shown that the clonal identity of multiple gut-
480 colonizing *E. coli* strains can be directly determined in fecal samples by deep
481 sequencing of just two genetic loci – *fumC* and *fimH* (CH typing) [55].

482 While predicting the probability of UTI in certain risk groups could be of
483 practical interest, we believe that, if a clinical infection develops, it is even more
484 important to accurately predict the antibiotic susceptibility of the pathogen. We
485 demonstrate here that, within up to 18 months of fecal sample analysis, the
486 resistance of the gut resident *E. coli* – dubbed here as FECAR test - served as
487 a valuable predictive tool for estimating the susceptibility of the UTI-causing

488 bacteria for the three tested antibiotics. Though this conclusion is based on the
489 limited testing and data we have for our population in the study, the significant
490 improvement in the potential antibiotic choice is reflected by the 'excellent'
491 discrimination level of FECAR for the resistance to TMP/STX, CIP and 3GC
492 based on the AUC values between 0.8 and 0.9 [49]. Due to the relatively low
493 overall resistance to third-generation cephalosporins (3GC), the reduction in
494 drug-bug mismatch rates in the allowed cases was not as obvious as with
495 TMP/STX and CIP, but the AUC value was also at the excellent level. Moreover,
496 because *E. coli* was responsible for nearly 90% of CA-UTI cases, the diagnostic
497 prediction was also excellent for all UTI cases overall. Thus, the accuracy of
498 predicting resistance profiles of UTI-causing *E. coli* based on the fecal sample
499 collected within 18 months is sufficiently high to warrant further studies to
500 develop this approach as a predictive tool for antibiotic selection in UTI. The
501 FECAR-guided empirical choice of antibiotics could lead to a several-fold
502 reduction of the drug-bug mismatches relatively to the unguided treatment.

503 Naturally, the correlation between the resistance profiles of gut *E. coli* and that
504 of urine *E. coli* suggests that the strains causing UTIs derived from the gut
505 colonizers. Indeed, clonal identity was established between the vast majority of
506 fecal and urine strains with matching resistance profiles when they were
507 obtained from the same individual. In our study, strain clonality was determined
508 by a highly discriminatory sub-ST genotyping method [58, 59], strongly implying
509 the identity of the strains that was confirmed by whole genome sequencing of
510 representative strain pairs.

511 Previous studies varied significantly in their estimates of the duration of gut
512 colonization by specific *E. coli* strains – ranging from several days to a few
513 years, with a possible existence of 'transient' colonizers with a short-lived gut
514 residence span and long-term 'resident' colonizers with a much slower turnover
515 [60]. Though our study did not analyze the duration of gut colonization per se, it
516 suggests that uropathogenic antibiotic-resistant strains can reside in the gut for
517 a relatively long time, making the 18-month predictability of the urinary
518 pathogen feasible. This corresponds to previous studies suggesting that *E. coli*
519 H30 and ST1193 strains may be well-adapted as colonizers [12, 34, 35, 61].
520 Moreover, it has been proposed that the genetic factors contributing to gut
521 colonization could serve as evolutionary pre-adapted (coincidental) urovirulence
522 factors [62, 63]. Finally, our results support the hypotheses that persistent gut
523 colonization by antibiotic-resistant *E. coli* may not necessarily depend on an
524 antibiotic use by the host [26].

525 The human gut is usually colonized by multiple strains of *E. coli* simultaneously.
526 For example, it has been shown that *E. coli* H30 in the gut is found, on average,
527 with 1-2 other strains, often exhibiting different resistance profiles and in
528 different relative proportions. While in the current study, the genetic diversity of
529 gut resident *E. coli* was not analyzed, colonization by multiple strains is
530 expected for most enrollees. For example, the fact that in certain carriers of
531 resistant strains, UTIs were caused by sensitive strains could be due, at least in
532 some cases, to the possibility that resistant strains were co-colonizing the gut
533 with a sensitive strain that eventually caused the infection. Alternatively, this

534 could have happened because the resistant strain found originally in the fecal
535 sample was replaced by the sensitive strain as part of the strains' turnover. Gut
536 strains dynamics could also explain the fact that, in a small number of cases,
537 UTI was caused by a resistant strain not found in the fecal sample, which could
538 be acquired by the host after the original sample collection. This, however,
539 should be resolved in future studies.

540 It remains to be determined whether a more detailed exploration of gut *E. coli*
541 strains' diversity, fecal abundance, the presence/absence of putative virulence
542 factors, and different resistance genes could further improve the prediction of
543 the UTI risks and optimal treatment. In addition to validating our results, future
544 studies should also assess whether FECAR could be used for prediction of the
545 UTI pathogens resistance to a broader spectrum of antibiotics. Furthermore, the
546 strain-dependent UTI risks need to be delineated across various age groups and
547 genders, considering additional host factors such as co-morbidities,
548 immunodeficiency status, etc. Despite the limitations of our study and remaining
549 questions, we strongly believe that discerning gut *E. coli* profiles should become
550 an integral component of the personalized medicine approach in UTI
551 management. Additionally, our findings should prompt further research in the
552 development of innovative strategies to prevent UTIs by, for example,
553 selectively decolonizing gut carriers of highly urovirulent and/or multi-drug
554 resistant enterobacterial strains. This may not only diminish risks for severe
555 complications in the most vulnerable individuals but also contributes to curbing

556 the antimicrobial resistance pandemic by reducing the transmission and
557 community circulation of these pathogens.

558 **Acknowledgments**

559 This work was supported by the National Institutes of Health R01AI106007 and
560 R01AI150152 to EVS.

561 **References**

- 562 1. NIH. PERSONALIZED MEDICINE. Available at:
563 <https://www.genome.gov/genetics-glossary/Personalized-Medicine>.
564 Accessed 2/23/2024.
- 565 2. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut
566 microbiota on human health: an integrative view. *Cell* **2012**; 148(6):
567 1258-70.
- 568 3. Wilson M. *The Human Microbiota in Health and Disease: An Ecological
569 and Community-based Approach*. 1st Edition ed. New York: Taylor &
570 Francis group, **2018**.
- 571 4. Donskey CJ. The role of the intestinal tract as a reservoir and source
572 for transmission of nosocomial pathogens. *Clin Infect Dis* **2004**; 39(2):
573 219-26.

- 574 5. Johnson JR, Russo TA. Extraintestinal pathogenic *Escherichia coli*:
575 "the other bad E coli". J Lab Clin Med **2002**; 139(3): 155-62.
- 576 6. Lamberte LE, van Schaik W. Antibiotic resistance in the commensal
577 human gut microbiota. Curr Opin Microbiol **2022**; 68: 102150.
- 578 7. Bruxvoort KJ, Bider-Canfield Z, Casey JA, et al. Outpatient Urinary
579 Tract Infections in an Era of Virtual Healthcare: Trends From 2008 to
580 2017. Clin Infect Dis **2020**; 71(1): 100-8.
- 581 8. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol
582 **2010**; 7(12): 653-60.
- 583 9. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention,
584 and treatment of catheter-associated urinary tract infection in adults:
585 2009 International Clinical Practice Guidelines from the Infectious
586 Diseases Society of America. Clin Infect Dis **2010**; 50(5): 625-63.
- 587 10. Yang X, Chen H, Zheng Y, Qu S, Wang H, Yi F. Disease burden and
588 long-term trends of urinary tract infections: A worldwide report. Front
589 Public Health **2022**; 10: 888205.
- 590 11. Tchesnokova V, Riddell K, Scholes D, Johnson JR, Sokurenko EV. The
591 Uropathogenic *Escherichia coli* Subclone Sequence Type 131-H30 Is
592 Responsible for Most Antibiotic Prescription Errors at an Urgent Care
593 Clinic. Clin Infect Dis **2019**; 68(5): 781-7.

- 594 12. Tchesnokova VL, Rechkina E, Larson L, et al. Rapid and Extensive
595 Expansion in the United States of a New Multidrug-resistant
596 *Escherichia coli* Clonal Group, Sequence Type 1193. Clin Infect Dis
597 **2019**; 68(2): 334-7.
- 598 13. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract
599 infection: self-reported incidence and associated costs. Ann Epidemiol
600 **2000**; 10(8): 509-15.
- 601 14. Saint S. Clinical and economic consequences of nosocomial catheter-
602 related bacteriuria. Am J Infect Control **2000**; 28(1): 68-75.
- 603 15. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for
604 adults in ambulatory care in the USA, 2007-09. J Antimicrob
605 Chemother **2014**; 69(1): 234-40.
- 606 16. Dellit TH, Owens RC, McGowan JE, Jr., et al. Infectious Diseases
607 Society of America and the Society for Healthcare Epidemiology of
608 America guidelines for developing an institutional program to enhance
609 antimicrobial stewardship. Clin Infect Dis **2007**; 44(2): 159-77.
- 610 17. Jenkins SG, Schuetz AN. Current concepts in laboratory testing to
611 guide antimicrobial therapy. Mayo Clin Proc **2012**; 87(3): 290-308.

- 612 18. Thorpe KE, Joski P, Johnston KJ. Antibiotic-Resistant Infection
613 Treatment Costs Have Doubled Since 2002, Now Exceeding \$2 Billion
614 Annually. *Health Aff (Millwood)* **2018**; 37(4): 662-9.
- 615 19. Moon RC, Marijam A, Mitrani-Gold FS, et al. Treatment patterns,
616 healthcare resource use, and costs associated with uncomplicated
617 urinary tract infection among female patients in the United States.
618 *PLoS One* **2022**; 17(11): e0277713.
- 619 20. Gupta K, Hooton TM, Naber KG, et al. International clinical practice
620 guidelines for the treatment of acute uncomplicated cystitis and
621 pyelonephritis in women: A 2010 update by the Infectious Diseases
622 Society of America and the European Society for Microbiology and
623 Infectious Diseases. *Clin Infect Dis* **2011**; 52(5): e103-20.
- 624 21. IDSA. Combating Antimicrobial Resistance: Policy Recommendations
625 to Save Lives. *Clin Infect Dis* **2011**; 52(Suppl 5): S397-S428.
- 626 22. Gupta K, Grigoryan L, Trautner B. Urinary Tract Infection. *Ann Intern*
627 *Med* **2017**; 167(7): ITC49-ITC64.
- 628 23. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract
629 infections: epidemiology, mechanisms of infection and treatment
630 options. *Nat Rev Microbiol* **2015**; 13(5): 269-84.

- 631 24. Tchesnokova V, Larson L, Basova I, et al. Increase in the community
632 circulation of ciprofloxacin-resistant *Escherichia coli* despite reduction
633 in antibiotic prescriptions. *Commun Med (Lond)* **2023**; 3(1): 110.
- 634 25. Tchesnokova VL, Rechkina E, Chan D, et al. Pandemic Uropathogenic
635 Fluoroquinolone-resistant *Escherichia coli* Have Enhanced Ability to
636 Persist in the Gut and Cause Bacteriuria in Healthy Women. *Clin Infect*
637 *Dis* **2020**; 70(5): 937-9.
- 638 26. Lehtinen S, Blanquart F, Croucher NJ, Turner P, Lipsitch M, Fraser C.
639 Evolution of antibiotic resistance is linked to any genetic mechanism
640 affecting bacterial duration of carriage. *Proc Natl Acad Sci U S A* **2017**;
641 114(5): 1075-80.
- 642 27. Davies NG, Flasche S, Jit M, Atkins KE. Within-host dynamics shape
643 antibiotic resistance in commensal bacteria. *Nat Ecol Evol* **2019**; 3(3):
644 440-9.
- 645 28. Hu Y, Matsui Y, L WR. Risk factors for fecal carriage of drug-resistant
646 *Escherichia coli*: a systematic review and meta-analysis. *Antimicrob*
647 *Resist Infect Control* **2020**; 9(1): 31.
- 648 29. Tchesnokova V, Radey M, Chattopadhyay S, et al. Pandemic
649 fluoroquinolone resistant *Escherichia coli* clone ST1193 emerged via

- 650 simultaneous homologous recombinations in 11 gene loci. Proc Natl
651 Acad Sci U S A **2019**; 116(29): 14740-8.
- 652 30. Pitout JD, DeVinney R. *Escherichia coli* ST131: a multidrug-resistant
653 clone primed for global domination. F1000Res **2017**; 6.
- 654 31. Pitout JDD, Peirano G, Chen L, DeVinney R, Matsumura Y. *Escherichia*
655 *coli* ST1193: Following in the Footsteps of *E. coli* ST131. Antimicrob
656 Agents Chemother **2022**; 66(7): e0051122.
- 657 32. Johnson JR, Tchesnokova V, Johnston B, et al. Abrupt emergence of a
658 single dominant multidrug-resistant strain of *Escherichia coli*. J Infect
659 Dis **2013**; 207(6): 919-28.
- 660 33. Price LB, Johnson JR, Aziz M, et al. The epidemic of extended-
661 spectrum-beta-lactamase-producing *Escherichia coli* ST131 is driven
662 by a single highly pathogenic subclone, H30-Rx. MBio **2013**; 4(6):
663 e00377-13.
- 664 34. Sarkar S, Hutton ML, Vagenas D, et al. Intestinal Colonization Traits of
665 Pandemic Multidrug-Resistant *Escherichia coli* ST131. J Infect Dis
666 **2018**; 218(6): 979-90.
- 667 35. Fuzi M, Sokurenko E. Commensal Fitness Advantage May Contribute
668 to the Global Dissemination of Multidrug-Resistant Lineages of
669 Bacteria-The Case of Uropathogenic *E. coli*. Pathogens **2023**; 12(9).

- 670 36. Marcusson LL, Frimodt-Moller N, Hughes D. Interplay in the selection
671 of fluoroquinolone resistance and bacterial fitness. *PLoS Pathog* **2009**;
672 5(8): e1000541.
- 673 37. Campos-Madueno EI, Moradi M, Eddoubaji Y, et al. Intestinal
674 colonization with multidrug-resistant Enterobacterales: screening,
675 epidemiology, clinical impact, and strategies to decolonize carriers. *Eur*
676 *J Clin Microbiol Infect Dis* **2023**; 42(3): 229-54.
- 677 38. Denkel LA, Maechler F, Schwab F, et al. Infections caused by
678 extended-spectrum beta-lactamase-producing Enterobacterales after
679 rectal colonization with ESBL-producing *Escherichia coli* or *Klebsiella*
680 *pneumoniae*. *Clin Microbiol Infect* **2020**; 26(8): 1046-51.
- 681 39. Magruder M, Sholi AN, Gong C, et al. Gut uropathogen abundance is a
682 risk factor for development of bacteriuria and urinary tract infection.
683 *Nat Commun* **2019**; 10(1): 5521.
- 684 40. Grasselli G, Scaravilli V, Alagna L, et al. Gastrointestinal colonization
685 with multidrug-resistant Gram-negative bacteria during extracorporeal
686 membrane oxygenation: effect on the risk of subsequent infections and
687 impact on patient outcome. *Ann Intensive Care* **2019**; 9(1): 141.

- 688 41. Forsyth JH, Barron NL, Scott L, et al. Decolonizing drug-resistant *E.*
689 *coli* with phage and probiotics: breaking the frequency-dependent
690 dominance of residents. *Microbiology (Reading)* **2023**; 169(7).
- 691 42. Ghani R, Mullish BH, McDonald JAK, et al. Disease Prevention Not
692 Decolonization: A Model for Fecal Microbiota Transplantation in
693 Patients Colonized With Multidrug-resistant Organisms. *Clin Infect Dis*
694 **2021**; 72(8): 1444-7.
- 695 43. Davido B, Salomon J, Lawrence C, et al. Impact of Fecal Microbiota
696 Transplantation for Decolonization of Multidrug-Resistant Organisms
697 May Vary According to Donor Microbiota. *Clin Infect Dis* **2018**; 66(8):
698 1316-7.
- 699 44. Dinh A, Duran C, Bouchand F, Salomon J, Davido B. Fecal Microbiota
700 Transplantation Is a New Effective Weapon to Fight Multidrug-
701 Resistant Bacteria, but Harmonization and More Data Are Needed. *Clin*
702 *Infect Dis* **2017**; 65(8): 1425-6.
- 703 45. Geerlings SE. Clinical Presentations and Epidemiology of Urinary Tract
704 Infections. *Microbiol Spectr* **2016**; 4(5).
- 705 46. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. *N*
706 *Engl J Med* **2012**; 366(11): 1028-37.

- 707 47. Foxman B. Urinary tract infection syndromes: occurrence, recurrence,
708 bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am*
709 **2014**; 28(1): 1-13.
- 710 48. Yang JL, Wang MS, Cheng AC, Pan KC, Li CF, Deng SX. A simple and
711 rapid method for extracting bacterial DNA from intestinal microflora for
712 ERIC-PCR detection. *World J Gastroenterol* **2008**; 14(18): 2872-6.
- 713 49. Hosmer D, Lemeshow, S. *Applied Logistic Regression*, **2000**.
- 714 50. Raz R, Gennesin Y, Wasser J, et al. Recurrent urinary tract infections
715 in postmenopausal women. *Clin Infect Dis* **2000**; 30(1): 152-6.
- 716 51. Hooton TM. Recurrent urinary tract infection in women. *Int J Antimicrob*
717 *Agents* **2001**; 17(4): 259-68.
- 718 52. Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated
719 treatment of uncomplicated recurrent urinary tract infections in young
720 women. *Ann Intern Med* **2001**; 135(1): 9-16.
- 721 53. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al.
722 Intercontinental emergence of *Escherichia coli* clone O25:H4-ST131
723 producing CTX-M-15. *J Antimicrob Chemother* **2008**; 61(2): 273-81.
- 724 54. Johnson JR, Thuras P, Johnston BD, et al. The Pandemic H30
725 Subclone of *Escherichia coli* Sequence Type 131 Is Associated With

- 726 Persistent Infections and Adverse Outcomes Independent From Its
727 Multidrug Resistance and Associations With Compromised Hosts. Clin
728 Infect Dis **2016**; 62(12): 1529-36.
- 729 55. Shevchenko SG, Radey M, Tchesnokova V, Kisiela D, Sokurenko EV.
730 *Escherichia coli* Clonobiome: Assessing the Strain Diversity in Feces
731 and Urine by Deep Amplicon Sequencing. Appl Environ Microbiol **2019**;
732 85(23).
- 733 56. Wirth T, Falush D, Lan R, et al. Sex and virulence in *Escherichia coli*:
734 an evolutionary perspective. Mol Microbiol **2006**; 60(5): 1136-51.
- 735 57. Tchesnokova V, Billig M, Chattopadhyay S, et al. Predictive
736 diagnostics for *Escherichia coli* infections based on the clonal
737 association of antimicrobial resistance and clinical outcome. J Clin
738 Microbiol **2013**; 51(9): 2991-9.
- 739 58. Roer L, Johannesen TB, Hansen F, et al. CHTyper, a Web Tool for
740 Subtyping of Extraintestinal Pathogenic *Escherichia coli* Based on the
741 *fumC* and *fimH* Alleles. J Clin Microbiol **2018**; 56(4).
- 742 59. Weissman SJ, Johnson JR, Tchesnokova V, et al. High-resolution two-
743 locus clonal typing of extraintestinal pathogenic *Escherichia coli*. Appl
744 Environ Microbiol **2012**; 78(5): 1353-60.

- 745 60. Martinson JNV, Walk ST. *Escherichia coli* Residency in the Gut of
746 Healthy Human Adults. *EcoSal Plus* **2020**; 9(1).
- 747 61. Morales Barroso I, Lopez-Cerero L, Navarro MD, Gutierrez-Gutierrez B,
748 Pascual A, Rodriguez-Bano J. Intestinal colonization due to
749 *Escherichia coli* ST131: risk factors and prevalence. *Antimicrob Resist*
750 *Infect Control* **2018**; 7: 135.
- 751 62. Adiba S, Nizak C, van Baalen M, Denamur E, Depaulis F. From grazing
752 resistance to pathogenesis: the coincidental evolution of virulence
753 factors. *PLoS One* **2010**; 5(8): e11882.
- 754 63. Le Gall T, Clermont O, Gouriou S, et al. Extraintestinal virulence is a
755 coincidental by-product of commensalism in B2 phylogenetic group
756 *Escherichia coli* strains. *Mol Biol Evol* **2007**; 24(11): 2373-84.
- 757

758 Table 1. Prevalence of different *E. coli* among women of different age

Characteristic ^a	Total	Age (yo)				P value ^b	
		No. (%)	50-59	60-69	70-79		80+
		No. (%)	No. (%)	No. (%)	No. (%)		
Total	1804 (100)	437 (100)	632 (100)	532 (100)	203 (100)		
<i>E. coli</i> present	1638 (90.8)	388 (88.8)	561 (88.8)	500 (94)	189 (93.1)	.001	
<i>E. coli</i> absent	166 (9.2)	49 (11.2)	71 (11.2)	32 (6)	14 (6.9)		
All-sensitive <i>E. coli</i>	1023 (62.5)	244 (62.9)	353 (62.9)	308 (61.6)	118 (62.4)	.583	
3GC-R <i>E. coli</i>	129 (7.9)	26 (6.7)	46 (8.2)	41 (8.2)	16 (8.5)	.612	
TMP/STX-R <i>E. coli</i>	395 (24.1)	91 (23.5)	130 (23.2)	126 (25.2)	48 (25.4)	.215	

CIP-R <i>E. coli</i>	318 (19.4)	74 (19.1)	113 (20.1)	97 (19.4)	34 (18)	. 655
H30	70 (4.3)	9 (2.3)	24 (4.3)	22 (4.4)	15 (7.9)	.001
ST1193	68 (4.2)	20 (5.2)	25 (4.5)	19 (3.8)	4 (2.1)	.057

759

760 ^a Prevalence of any or no *E. coli* carrying samples was calculated as percent from total number of samples;
761 prevalence of resistant *E. coli* carrying samples was calculated as percent of any *E. coli* carrying samples.

762 ^b P values were derived from logistic regression using age in years as predictor and *E. coli* carriage as
763 outcome, with sensitive/resistant *E. coli* carriage restricted for overall *E. coli* carriage in a sample; P < .05
764 in bold.

765

766 Table 2. UTI rates among different groups

Characteristic ^a	Total	P value	Age (yo)				P value ^f
			No. (%)				
			50-59	60-69	70-79	80+	
		No. (%)	No. (%)	No. (%)	No. (%)		
Total	184 (10.2)		28 (6.4)	51 (8.1)	65 (12.2)	40 (19.7)	<.001
<i>E. coli</i> present	179 (10.9)	.0013 ^b	27 (7)	49 (8.7)	64 (12.8)	39 (20.6)	<.001
<i>E. coli</i> absent	5 (3.0)		1 (2)	2 (2.8)	1 (3.1)	1 (7.1)	.796
All-sensitive <i>E. coli</i>	121 (11.8)	.252 ^c	22 (9)	33 (9.3)	45 (14.6)	22 (18.6)	.001
3GC-R <i>E. coli</i>	12 (9.3)	.381 ^d	1 (3.8)	4 (8.7)	4 (9.8)	3 (18.8)	.218
TMP/STX-R <i>E. coli</i>	36 (9.1)	.131 ^d	5 (5.5)	9 (6.9)	10 (7.9)	12 (25)	.002

CIP-R <i>E. coli</i>	43 (13.5)	.449 ^d	4 (5.4)	13 (11.5)	14 (14.4)	12 (35.3)	<.001
H30	17 (24.3)	.0003 ^e	0 (0)	3 (12.5)	8 (36.4)	6 (40.0)	<.001
ST1193	8 (11.8)	.821 ^e	2 (10)	4 (16)	2 (10.5)	0 (0)	.927

767 ^a UTI rates are calculated as percentage of patients who had UTI from total number of females in this
768 group.

769 ^b P value calculated in Chi-square test comparing UTI in *E. coli* carriers vs non-carriers; P < .05 in bold.

770 ^c P value calculated in Chi-square test comparing UTI in any resistant vs all sensitive *E. coli* carriers.

771 ^d P value calculated in Chi-square test comparing UTI in carriers of *E. coli* resistant to particular group of
772 antibiotics vs all sensitive *E. coli*.

773 ^e P value calculated in Chi-square test comparing UTI in H30 or ST1193 vs any other *E. coli* carriers; P <
774 .05 in bold.

775 ^f P values calculated in logistic regression with age as a predictor, unconstrained or constrained by group

776 predictor; P < .05 in bold

777

778 **Table 3. Coincidence of sensitive and resistant *E. coli* in clinical urine samples with identified**
 779 **uropathogen (N = 134) and respective fecal samples.**

Characteristic	UTI No. (%)	<i>E. coli</i> in Fecal sample No. (% UTI)	Overlap No. (% UTI)	P value ^a
Total UTI with identified uropathogen	134 (100)			
UTI caused by <i>E. coli</i> (% total)	118 (88.1)	118 (100)	118 (100)	< .001
All-sensitive <i>E. coli</i> (% <i>E. coli</i> UTI)	82 (69.5)	73 (54.9)	69 (84.1)	< .001
CIP-R <i>E. coli</i> (% <i>E. coli</i> UTI)	19 (16.1)	31 (23.3)	17 (89.5)	< .001
TMP/STX-R <i>E. coli</i> (% <i>E. coli</i> UTI)	19 (16.1)	27 (20.3)	17 (89.5)	< .001
3GC-R <i>E. coli</i> (% <i>E. coli</i> UTI)	5 (4.2)	9 (6.8)	4 (80)	< .001

UTI caused by non- <i>E. coli</i> (% total)	16 (11.9)	15 (93.8)	N/A ^b	
All-sensitive non- <i>E. coli</i> (% of non- <i>E. coli</i> uropathogen)	16 (100)	12 (75)	12 (75)	< .001

780

781 ^a P value calculated in logistic regression of the outcome (uropathogen) from predictor (fecal *E. coli*)

782 ^b N/A, not applicable

783 Table 4. Urinary *E. coli* prediction based on fecal *E. coli* sensitivity test results.

<i>E. coli</i> in sample	<i>E. coli</i> UTI (N = 118)			All known bug UTI (N = 134)		
	PPV, % [CI95]	NPV, % [CI95]	AUC ^a	PPV, % [CI95]	NPV, % [CI95]	AUC ^a
All sensitive <i>E. coli</i>	94.5 [86.6, 98.5]	71.1 [55.7, 83.6]	0.8577	95.3 [88.5, 98.7]	66.7 [51.6, 79.6]	0.8577
CIP-S <i>E. coli</i>	97.7 [91.9, 99.7]	54.8 [36.0, 72.7]	0.8767	98.0 [93.1, 99.7]	53.1 [34.7, 70.9]	0.8822
TMP/STX-S <i>E. coli</i>	97.8 [92.3, 99.7]	63.0 [42.4, 80.6]	0.8894	98.1 [93.2, 99.7]	58.6 [38.9, 76.5]	0.8908
3GC-S <i>E. coli</i>	99.1	44.4	0.8779	99.2	44.4	0.8806

[95.0, 100.0] [13.7, 78.8]

[95.6, 100.0] [13.7, 78.8]

784

785 ^a AUC, Receiving Operator Curve analysis (ROC) Area Under Curve

786

787 **Table 5. Predictive power of knowing fecal bacterial resistance for**
 788 **treatment of UTI.**

789

Antibiotic	Allowed		Resistance in allowed		Resistance overall		P value
	No.	%	No.	%	No.	%	
TMP/STX	105	78.4	2	1.9	19	14.2	.0009
CIP	102	76.1	2	2.0	19	14.2	.0011
3GC	125	93.2	1	0.8	5	3.7	.0963
TMP/STX or CIP	120	89.6	N/A	N/A	N/A	N/A	N/A
TMP/STX or 3GC	127	94.8	N/A	N/A	N/A	N/A	N/A
CIP or 3GC	126	94.0	N/A	N/A	N/A	N/A	N/A
TMP/STX or CIP or 3GC	127	94.8	N/A	N/A	N/A	N/A	N/A

790 N/A, not applicable

791 **Supporting information**

792 **S1 Fig.** Analysis of gut *E. coli* carriage and UTI incidence by age.

793 **S2 Fig.** UTI incidence rates and uropathogens characteristics.

794 **S3 Fig.** Phylogenetic relationship between fecal (F) and clinical urine (CU) *E.*
795 *coli* belonging to the same clonal group but isolated from different patients.

796 **S1 Table.** UTI *E. coli* resistant to antibiotics.

797 **S2 Table.** Non- *E. coli* UTI uropathogens.

798 **S3 Table.** All data by enrollee.